Scottish Medicines Consortium accepts three new medicines

The Scottish Medicines Consortium (SMC), which advises NHSScotland on newly licensed medicines, has published advice accepting three new medicines. The SMC Committee accepted the following drugs: Llutetium oxotretide (Lutathera) for the treatment of rare tumours that develop in the gut or pancreas. Lutetium oxotretide is a type of cancer medicine called a radiopharmaceutical (a medicine that emits a small amount of radioactivity). Through SMC’s Patient and Clinician Engagement (PACE) process for medicines used to treat very rare and end of life conditions, patients and clinicians described the debilitating symptoms of this condition which have a negative impact on patients’ day